SweetValueLab
Write for us

Colgate-Palmolive Company — Intrinsic Value & Fair Price

CL
NYSEConsumer DefensiveHousehold & Personal ProductsCIK 0000021665colgatepalmolive.comAbout CL
Last close · Oct 16, 202694.11+1.44 (+1.55%)
Market cap$75.0B
Model value · DCF · Perpetuity growth · 5y
69.43
Colgate-Palmolive closed at $94.11 — overvalued by 36% vs model.
38.26the model's range193.00

DCF · Perpetuity growth · 5y leads for a mature, steady company — positive operating income and three years of positive free cash flow. From a five-year discounted cash flow.

Other models
42.72 – 104.33
Wall St. target
104.00 10% below
Above model, 1y
20 of 21 days

Price and model value

Embed this card

CL's close against its model value, as a 420×168 card for your own page. It updates nightly with this site and links back here.

Free to embed; keep the attribution link.
Loading chart…
What the marks mean
Daily close

Dividends

Quarterly · as of Oct 16, 2026
Yield, trailing 12 months
2.23%
Past 2 years
low 1.80%high 2.75%
Dividends per share, a year at a time
$1.78Jul ’21$1.84Jul ’22$1.90Jul ’23$1.96Jul ’24$2.04Jul ’25$2.10TTM
Coverage
—
Raised
52+ years in a row
Growth, 5 yrs
3.4% a year
Last change
+1.9% · Apr 2026
Every payment, with ex-dates · latest $0.53, paid Aug 14, 2026

Research on CL

No posts on CL yet.
Studied CL from its filings? Guest posts are reviewed before they go live.Write about CL →

How it is valued

Valued asMature & stable
Low/slowing growth (~2% recent)Moderate margins (10% net margin)Highly cyclical earningsHigh leverage (D/E 147.9x)
What growth the price implies: the reverse DCF

Key figures

FY2025 · chosen for mature companies
P/E
35.8×
EV / EBITDA
20.7×
FCF yield
4.8%
Dividend yield, TTM
2.23%
Beta
0.32
Cost of capital (WACC)
7.00%
Full financials

Analyst actions

third-party, quoted
10-15UBS · target106.00
09-21Piper Sandler · target95.00
08-03RBC Capital · target104.00
04-21Rothschild& Co · “Buy” from “Neutral”upgrade
Ratings, targets and estimates

Comparable companies

by business, not by industry label
Side by side:vs PG

The weekly

One email a week across every stock we cover: 13F filings, insider trades, earnings and new research. It covers the whole market, not just CL. No account.

About Colgate-Palmolive

Operating globally, Colgate-Palmolive Company and its affiliated entities are engaged in the production and distribution of a diverse range of consumer goods. Its operations are structured into two primary divisions: Oral, Personal and Home Care, and Pet Nutrition. The Oral, Personal and Home Care division encompasses a broad array of offerings, spanning oral hygiene (e.g., toothpastes, toothbrushes, mouthwashes), personal care (e.g., bar and liquid soaps, shower gels, shampoos, conditioners, deodorants, antiperspirants, skin health items), and home care solutions (e.g., dishwashing detergents, fabric conditioners, household cleaners). These products are distributed through various channels, including traditional and online retailers, wholesalers, and distributors, under well-known brand names such as Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly. Furthermore, this segment supplies specialized pharmaceutical products to dentists and other professionals in oral healthcare. Conversely, the Pet Nutrition segment focuses on providing specialized pet food. This includes everyday nutritional options marketed under the Hill's Science Diet brand, as well as therapeutic diets designed to assist in managing various health conditions in dogs and cats, sold under the Hill's Prescription Diet brand. Distribution for these pet nutrition items occurs via pet supply stores, veterinary clinics, and online retail platforms. Established in 1806, Colgate-Palmolive Company maintains its corporate headquarters in New York, New York.

CEO
Noel R. Wallace
Headquarters
New York City, NY
Employees
33,600
IPO
1973-05-02
Full company profile

Model estimates for research reference only, not investment advice. Every model rests on assumptions that may not match what happens; the formulas are in how we value a stock.